On Wednesday, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s shares declined -15.26% to $9.05.
Achillion Pharmaceuticals, Inc. (ACHN) stated financial results for the three months ended March 31, 2015. For the first quarter of 2015, the Company stated a net loss of $19.3 million or $0.17 per share, contrast with a net loss of $16.1 million or $0.17 per share for the first quarter of 2014. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2015 were $275.9 million.
First Quarter 2015 Results
For the first quarter of 2015, the Company stated a net loss of $19.3 million, or $0.17 per share, contrast with a net loss of $16.1 million, or $0.17 per share for the first quarter of 2014. Cash, cash equivalents, marketable securities, and interest receivable as of March 31, 2015 were $275.9 million.
Research and development expenses were $15.2 million in the first quarter of 2015, contrast with $12.8 million for the same period of 2014. The enhance was primarily due to raised personnel and non-cash stock compensation costs due to the addition of personnel in our development group, combined with raised manufacturing costs related to ACH-3422 and raised preclinical costs related to our complement inhibitor program. These amounts were partially offset by reduced clinical trial costs related to our ACH-3102 and sofosbuvir combination and ACH-2684.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares dropped -13.24% to $0.295.
AEterna Zentaris Inc. (USA) (AEZS) stated financial and operating results for the first quarter ended March 31, 2015.
Research and development (“R&D”) costs, were $4.5 million for the three-month period ended March 31, 2015, contrast to $5.8 million for the same period in 2014. This decrease is attributable to lower comparative employee compensation and benefits costs, facilities rent and maintenance in addition to other costs. A substantial portion of this decrease is due to the realization of cost savings in connection with the Company’s global resource optimization program in addition to the lower comparative exchange rate of the EUR against the US dollar. This decrease was partly compensated by higher third-party costs, mostly related to the Company’s ZoptEC Phase 3 clinical trial in endometrial cancer.
Net loss for the three-month period ended March 31, 2015 was $9.7 million, or $0.13 per basic and diluted share, contrast to $4.4 million, or $0.08 per basic and diluted share, for the same period in 2014. This enhance in net loss is due largely to higher comparative SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D costs.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
At the end of Wednesday’s trade, China Distance Education Hldgs Ltd (ADR) (NYSE:DL)‘s shares dipped -9.35% to $18.71.
China Distance Education Hldgs Ltd (ADR) (DL) declared unaudited financial results for the second quarter of fiscal 2015 ended March 31, 2015.
Second Quarter Fiscal 2015 Financial and Operational Highlights
- Total course enrollments reached 516,000 in the second quarter of fiscal 2015, an enhance of 4.6% from the second quarter of fiscal 2014.
- Cash receipts from online course registration raised by 16.2% to $28.6 million from the second quarter of fiscal 2014.
- Net revenue raised by 22.4% to $22.3 million from $18.2 million in the preceding year period, meeting the Company’s guidance range of $21.6 million to $22.8 million.
- Gross profit raised by 30.7% to $11.2 million from $8.6 million in the preceding year period.
- Non-GAAP[1]gross profit raised by 31.3% to $11.2 million from $8.6 million in the preceding year period.
- Gross margin was 50.0%, contrast with 46.9% in the preceding year period. Non-GAAP[1]gross margin was 50.3%, contrast with 46.9% in the preceding year period.
- Operating income raised by 68.1% to $0.9 million from $0.5 million in the preceding year period.
- Non-GAAP[1]operating income raised by 112.6% to $1.4 million from $0.7 million in the preceding year period.
- Net income reduced by 5.8% to $1.2 million from $1.3 million in the preceding year period.
- Non-GAAP[1]net income raised by 21.8% to $1.8 million from $1.4 million in the preceding year period.
China Distance Education Holdings Limited provides online and offline education services, and sells related products in the People’s Republic of China. The company offers online professional education services in the accounting, healthcare, and engineering and construction industries; and other professional education courses, such as the national judicial examination, online test-preparation courses for self-taught learners pursuing higher education diplomas or degrees, test preparation courses for university students intending to take the graduate school entrance exam, and online language courses.
Eleven Biotherapeutics Inc (NASDAQ:EBIO), ended its Wednesday’s trading session with -9.26% loss, and closed at $2.94.
Eleven Biotherapeutics Inc (EBIO) declared top-line results from the OASIS study, the company’s first pivotal Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease. The co-primary endpoints of the Phase 3 study were the total corneal fluorescein staining score and the patient-stated measurement related to ocular pain and discomfort based on the ocular surface disease index (OSDI), comparing the mean change from baseline at week 12 for treatment with EBI-005 to treatment with vehicle control. In this study, EBI-005 did not meet either of these two co-primary endpoints.
There was no statistically noteworthy difference between the EBI-005 treated group and the vehicle control group on the co-primary endpoints or any secondary endpoints. Patients with dry eye disease in both the EBI-005 and vehicle treatment groups showed statistically noteworthy improvement from baseline on the co-primary endpoints. While the change from baseline on the co-primary endpoints was greater in the vehicle group than the EBI-005 group, the differences between the two groups were not statistically significant and the company believes the differences were not clinically meaningful. EBI-005 was generally well tolerated in the Phase 3 study with fewer than 5% of patients reporting eye irritation and no treatment related serious adverse events. About 13% of patients in the study stated some use of artificial tears, with no difference in artificial tear use between the EBI-005 treated and vehicle control groups. Overall, 92% of patients accomplished the study, with 33 patients having dropped out of the EBI-005 group and 20 patients having dropped out of the vehicle control group.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates comprise EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has accomplished Phase II clinical trial for the treatment of allergic conjunctivitis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
